| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Commercial Officer | Chief Commercial Officer
2 companies
Wiley Matthew T. is a Chief Commercial Officer at VYNE with holdings across 2 companies. Recent SEC Form 4 filings include 0 buys and 4 sells.
Estimated insider holdings value: $96K based on current market prices.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Oct 3, 2024 | BTAI Bioxcel Therapeutics, Inc. | Chief Commercial Officer | Sell | 6,272 | $0.55 | $3,449.60 | -24.8% | -28.7% | -71.3% | |
| Sep 16, 2024 | BTAI Bioxcel Therapeutics, Inc. | Chief Commercial Officer | Sale+OE | 215 | $0.69 | $148.52 | -5.1% | -36.5% | -70.8% | |
| Jun 17, 2024 | BTAI Bioxcel Therapeutics, Inc. | Chief Commercial Officer | Sale+OE | 244 | $1.26 | $308.10 | -6.5% | -51.9% | -92.3% | |
| Apr 4, 2024 | BTAI Bioxcel Therapeutics, Inc. | Chief Commercial Officer | Sale+OE | 1,008 | $2.64 | $2,656.18 | -25.2% | -59.9% | -96.2% |